Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | CYBB | P04839 | 2/20 | 0.32 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 0.32 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26982292 | 0.82 | ALDH1A1 (0.41) | ALDH1A1MAP3K14 | |
| SCHEMBL31753138 | 0.82 | SMN1; SMN2 (0.35) | SMN1; SMN2NPC1RAB9ASOAT1CYBB | |
| SCHEMBL9738280 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9ASOAT1CYBB | |
| SCHEMBL28873682 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ASOAT1HTR1A | |
| SCHEMBL767620 | 0.71 | ERN1 (0.41) | SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL29427022 | 0.69 | ALDH1A1 (0.46) | ALDH1A1MAP3K14 | |
| SCHEMBL16953812 | 0.69 | ALDH1A1 (0.46) | ALDH1A1MAP3K14 | |
| SCHEMBL3105747 | 0.68 | KDM1A (0.43) | SMN1; SMN2ALDH1A1NPC1RAB9ASOAT1 | |
| SCHEMBL26982160 | 0.68 | AHR (0.31) | HTR2B | |
| SCHEMBL18119745 | 0.66 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ASOAT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | SMN1; SMN2 3120/4885ALDH1A1 1939/4885NPC1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.